The NLRP3 inflammasome in burns: a novel potential therapeutic target

Abstract

Burns are an underestimated serious injury negatively impacting survivors physically, psychologically and economically, and thus are a considerable public health burden. Despite significant advancements in burn treatment, many burns still do not heal or develop serious complications/sequelae. The nucleotide-binding oligomerization domain-like receptors (NLRs) family pyrin domain-containing 3 (NLRP3) inflammasome is a critical regulator of wound healing, including burn wound healing. A better understanding of the pathophysiological mechanism underlying the healing of burn wounds may help find optimal therapeutic targets to promote the healing of burn wounds, reduce complications/sequelae following burn, and maximize the restoration of structure and function of burn skin. This review aimed to summarize current understanding of the roles and regulatory mechanisms of the NLRP3 inflammasome in burn wound healing, as well as the preclinical studies of the involvement of NLRP3 inhibitors in burn treatment, highlighting the potential application of NLRP3-targeted therapy in burn wounds.

Keywords

NLRP3 inflammasome / Burns / Non-healing wounds / Complications / Sequelae / Inhibitors

References

[1] Chen Z, Zhang M, Xie S, Zhang X, Tang S, Zhang C, et al. Global burden of thermal burns, 1990-2017: unbalanced distributions and temporal trends assessed from the global burden of disease study 2017. Burns: journal of the International Society for Burn Injuries. 2022; 48: 915-25.

[2] James SL, Lucchesi LR, Bisignano C, Castle CD, Dingels ZV, Fox JT, et al. Epidemiology of injuries from fire, heat and hot substances: global, regional and national morbidity and mortality estimates from the global burden of disease 2017 study. Injury prevention: journal of the International Society for Child and Adolescent Injury Prevention. 2020; 26: i36-45.

[3] Schaefer TJ, Tannan SC. Thermal Burns. In: Aboubakr S, Abu-Ghosh A, Ackley WB (eds.), StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023. St. Petersburg, Florida, United States: StatPearls Publishing LLC, 2023.

[4] Hyder AA, Sugerman DE, Puvanachandra P, Razzak J, El-Sayed H, Isaza A, et al. Global childhood unintentional injury surveillance in four cities in developing countries: a pilot study. Bull World Health Organ. 2009; 87: 345-52.

[5] Sanchez JL, Bastida JL, Martínez MM, Moreno JM, Chamorro JJ. Socio-economic cost and health-related quality of life of burn victims in Spain. Burns: journal of the International Society for Burn Injuries. 2008; 34: 975-81.

[6] Kaddoura I, Abu-Sittah G, Ibrahim A, Karamanoukian R, Papazian N. Burn injury: review of pathophysiology and therapeutic modalities in major burns. Annals of burns and fire disasters. 2017; 30: 95-102.

[7] Jeschke MG, van Baar ME, Choudhry MA, Chung KK, Gibran NS, Logsetty S. Burn injury. Nat Rev Dis Prim. 2020; 6: 11.

[8] Oryan A, Alemzadeh E, Moshiri A. Burn wound healing: present concepts, treatment strategies and future directions. J Wound Care. 2017; 26: 5-19.

[9] Ashouri S. An introduction to burns. Phys Med Rehabil Clin N Am. 2022; 33: 871-83.

[10] Cancio LC. Topical antimicrobial agents for burn wound care: history and current status. Surg Infect. 2021; 22: 3-11.

[11] Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019; 20: 3328. https://doi.org/10.3390/ijms20133328.

[12] He Y, Hara H, Núñez G. Mechanism and regulation of NLRP3 Inflammasome activation. Trends Biochem Sci. 2016; 41: 1012-21.

[13] Vinaik R, Abdullahi A, Barayan D, Jeschke MG. NLRP3 inflammasome activity is required for wound healing after burns. Translational research: the journal of laboratory and clinical medicine. 2020; 217: 47.

[14] Vinaik R, Stanojcic M, Jeschke MG. NLRP3 Inflammasome modulates post-burn lipolysis and hepatic fat infiltration via fatty acid synthase. Sci Rep. 2018; 8: 15197.

[15] Vinaik R, Barayan D, Jeschke MG. NLRP3 Inflammasome in inflammation and metabolism: identifying novel roles in Postburn adipose dysfunction. Endocrinology. 2020; 161:bqaa116. https://doi.org/10.1210/endocr/bqaa116.

[16] Huang W, Jiao J, Liu J, Huang M, Hu Y, Ran W, et al. MFG-E8 accelerates wound healing in diabetes by regulating “NLRP3 inflammasome-neutrophil extracellular traps” axis. Cell death discovery. 2020; 6: 84.

[17] Yang H, Zhang Y, Du Z, Wu T, Yang C. Hair follicle mesenchymal stem cell exosomal lncRNA H19 inhibited NLRP3 pyroptosis to promote diabetic mouse skin wound healing. Aging. 2023; 15: 791-809.

[18] Sorg H, Tilkorn DJ, Hager S, Hauser J, Mirastschijski U. Skin wound healing: an update on the current knowledge and concepts. European surgical research Europaische chirurgische Forschung Recherches chirurgicales europeennes. 2017; 58: 81-94.

[19] Rodrigues M, Kosaric N, Bonham CA, Gurtner GC. Wound healing: a cellular perspective. Physiol Rev. 2019; 99: 665-706.

[20] Martin P, Nunan R. Cellular and molecular mechanisms of repair in acute and chronic wound healing. Br J Dermatol. 2015; 173: 370-8.

[21] Wilkinson HN, Hardman MJ. Wound healing: cellular mechanisms and pathological outcomes. Open Biol. 2020; 10: 200223. https://doi.org/10.1098/rsob.200223.

[22] D’Arpa P, Leung KP. Toll-like receptor Signaling in burn wound healing and scarring. Adv Wound Care (New Rochelle). 2017; 6: 330-43.

[23] Rani M, Nicholson SE, Zhang Q, Schwacha MG. Damage-associated molecular patterns (DAMPs) released after burn are associated with inflammation and monocyte activation. Burns: journal of the International Society for Burn Injuries. 2017; 43: 297-303.

[24] Wilgus TA, Roy S, McDaniel JC. Neutrophils and wound repair: positive actions and negative reactions. Adv Wound Care (New Rochelle). 2013; 2: 379-88.

[25] Mulder PPG, Vlig M, Boekema B, Stoop MM, Pijpe A, van Zuijlen PPM, et al. Persistent systemic inflammation in patients with severe burn injury is accompanied by influx of immature neutrophils and shifts in T cell subsets and cytokine profiles. Front Immunol. 2020; 11: 11621222.

[26] DeLeo FR, Allen LH. Phagocytosis and neutrophil extracellular traps. Faculty reviews. 2020; 9: 25.

[27] Silva MT.Macrophage phagocytosis of neutrophils at inflammatory/infectious foci: a cooperative mechanism in the control of infection and infectious inflammation. J Leukoc Biol. 2011; 89: 675-83.

[28] Li M, Hou Q, Zhong L, Zhao Y, Fu X. Macrophage related chronic inflammation in non-healing wounds. Front Immunol. 2021; 12: 12681710.

[29] Raziyeva K, Kim Y, Zharkinbekov Z, Kassymbek K, Jimi S, Saparov A. Immunology of acute and chronic wound healing. Biomol Ther. 2021; 11: 700. https://doi.org/10.3390/biom11050700.

[30] Evers LH, Bhavsar D, Mailänder P. The biology of burn injury. Exp Dermatol. 2010; 19: 777-83.

[31] Boniakowski AE, Kimball AS, Jacobs BN, Kunkel SL, Gallagher KA. Macrophage-mediated inflammation in normal and diabetic wound healing. J Immunol (Baltimore, Md: 1950). 2017; 199: 17-24.

[32] Muthu K, He LK, Melstrom K, Szilagyi A, Gamelli RL, Shankar R. Perturbed bone marrow monocyte development following burn injury and sepsis promote hyporesponsive monocytes. Journal of burn care & research: official publication of the American Burn Association. 2008; 29: 12-21.

[33] Rowan MP, Cancio LC, Elster EA, Burmeister DM, Rose LF, Natesan S, et al. Burn wound healing and treatment: review and advancements. Critical care. London, England: BioMed Central (England), 2015; 19: 243.

[34] Wang Y, Beekman J, Hew J, Jackson S, Issler-Fisher AC, Parungao R, et al. Burn injury: challenges and advances in burn wound healing, infection, pain and scarring. Adv Drug Deliv Rev. 2018; 123: 3.

[35] Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev. 2006; 19: 403-34.

[36] Markiewicz-Gospodarek A, Kozioł M, Tobiasz M, Baj J, Radzikowska-Büchner E, Przekora A. Burn wound healing: clinical complications, medical care, treatment, and dressing types: the current state of knowledge for clinical practice. Int J Environ Res Public Health. 2022; 19: 1338. https://doi.org/10.3390/ijerph19031338.

[37] Barnett KC, Li S, Liang K, Ting JP. A 360° view of the inflammasome: mechanisms of activation, cell death, and diseases. Cell. 2023; 186: 2288-312.

[38] Li Y, Huang H, Liu B, Zhang Y, Pan X, Yu XY, et al. Inflammasomes as therapeutic targets in human diseases. Signal transduction and targeted therapy. 2021; 6: 247.

[39] Christgen S, Place DE, Kanneganti TD. Toward targeting inflammasomes: insights into their regulation and activation. Cell Res. 2020; 30: 315-27.

[40] Zhao Y, Shi J, Shi X, Wang Y, Wang F, Shao F. Genetic functions of the NAIP family of inflammasome receptors for bacterial ligands in mice. J Exp Med. 2016; 213: 647-56.

[41] Ranson N, Kunde D, Eri R. Regulation and sensing of Inflammasomes and their impact on intestinal health. Int J Mol Sci. 2017; 18: 2379. https://doi.org/10.3390/ijms18112379.

[42] Chen J, Chen ZJ. PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation. Nature. 2018; 564: 71-6.

[43] Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death. Cellular & molecular immunology. 2021; 18: 2114-27.

[44] Blevins HM, Xu Y, Biby S, Zhang S. The NLRP3 Inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci. 2022; 14: 14879021.

[45] Dai X, Tohyama M, Murakami M, Sayama K. Epidermal keratinocytes sense dsRNA via the NLRP3 inflammasome, mediating interleukin (IL)-1β and IL-18 release. Exp Dermatol. 2017; 26: 904-11.

[46] Xiao Y, Zhao C, Tai Y, Li B, Lan T, Lai E, et al. STING mediates hepatocyte pyroptosis in liver fibrosis by epigenetically activating the NLRP3 inflammasome. Redox Biol. 2023; 62: 102691.

[47] Shahzad K, Fatima S, Khawaja H, Elwakiel A, Gadi I, Ambreen S, et al. Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease. Kidney Int. 2022; 102: 766-79.

[48] Hsu CG, Li W, Sowden M, Chávez CL, Berk BC. Pnpt1 mediates NLRP3 inflammasome activation by MAVS and metabolic reprogramming in macrophages. Cellular & molecular immunology. 2023; 20: 131-42.

[49] Kunte SC, Marschner JA, Klaus M, Honda T, Li C, Motrapu M, et al. No NLRP3 inflammasome activity in kidney epithelial cells, not even when the NLRP3-A350V muckle-wells variant is expressed in podocytes of diabetic mice. Front Immunol. 2023; 14: 141230050.

[50] Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019; 19: 477-89.

[51] Shiohara M, Taniguchi S, Masumoto J, Yasui K, Koike K,Komiyama A,et al. ASC, which is composed of a PYD and a CARD, is up-regulated by inflammation and apoptosis in human neutrophils. Biochem Biophys Res Commun. 2002; 293: 1314-8.

[52] Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol (Baltimore, Md: 1950). 2009; 183: 787-91.

[53] Mosser DM, Zhang X. Activation of murine macrophages. Curr Protoc Immunol. 2008; 83:Chapter 14, pp. 14.12.11-14.12.18. https://doi.org/10.1002/0471142735.im1402s83.

[54] Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019; 10: 128.

[55] Gritsenko A, Yu S, Martin-Sanchez F, Diaz-Del-Olmo I, Nichols EM, Davis DM, et al. Priming is dispensable for NLRP3 Inflammasome activation in human monocytes In vitro. Front Immunol. 2020; 11: 565924.

[56] Ohto U, Kamitsukasa Y, Ishida H, Zhang Z, Murakami K, Hirama C, et al. Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation. Proc Natl Acad Sci USA. 2022; 119: e2121353119. https://doi.org/10.1073/pnas.2121353119.

[57] Swanton T, Beswick JA, Hammadi H, Morris L, Williams D, de Cesco S, et al. Selective inhibition of the K(+) efflux sensitive NLRP3 pathway by Cl(−) channel modulation. Chem Sci. 2020; 11: 11720-8.

[58] Xie H, Peng J, Zhang X, Deng L, Ding Y, Zuo X, et al. Effects of mitochondrial reactive oxygen species-induced NLRP3 inflammasome activation on trichloroethylene-mediated kidney immune injury. Ecotoxicol Environ Saf. 2022; 244: 114067.

[59] Gong Z, Pan J, Shen Q, Li M, Peng Y. Mitochondrial dysfunction induces NLRP3 inflammasome activation during cerebral ischemia/reperfusion injury. J Neuroinflammation. 2018; 15: 242.

[60] Shi H, Wang Y, Li X, Zhan X, Tang M, Fina M, et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat Immunol. 2016; 17: 250-8.

[61] Li S, Sun Y, Song M, Song Y, Fang Y, Zhang Q, et al. NLRP3/caspase-1/GSDMD-mediated pyroptosis exerts a crucial role in astrocyte pathological injury in mouse model of depression. JCI Insight. 2021; 6:e146852. https://doi.org/10.1172/jci.insight.146852.

[62] Lu Y, Sun Y, Xu K, Saaoud F, Shao Y, Ct D, et al. Aorta in pathologies may function as an immune organ by upregulating Secretomes for immune and vascular cell activation, differentiation and trans-differentiation-early Secretomes may serve as drivers for trained immunity. Front Immunol. 2022; 13: 13858256.

[63] Yeung K, Mraz V, Geisler C, Skov L, Bonefeld CM. The role of interleukin-1β in the immune response to contact allergens. Contact Derm. 2021; 85: 387-97.

[64] Sun Z, Liu H, Hu Y, Luo G, Yuan Z, Tu B, et al. STING contributes to trauma-induced heterotopic ossification through NLRP3-dependent macrophage pyroptosis. Clinical immunology (Orlando, Fla). 2023; 250: 109300.

[65] Ito H, Kanbe A, Sakai H, Seishima M. Activation of NLRP3 signalling accelerates skin wound healing. Exp Dermatol. 2018; 27: 80-6.

[66] Shi J, Tang Y, Liang F, Liu L, Liang N, Yang X, et al. NLRP3 inflammasome contributes to endotoxin-induced coagulation. Thromb Res. 2022; 214: 8.

[67] Boldeanu L, Boldeanu MV, Bogdan M, Meca AD, Coman CG, Buca BR, et al. Immunological approaches and therapy in burns (review). Experimental and therapeutic medicine. 2020; 20: 2361-7.

[68] Stanojcic M, Vinaik R, Abdullahi A, Chen P, Jeschke MG. NLRP3 knockout enhances immune infiltration and inflammatory responses and improves survival in a burn sepsis model. Immunology. 2022; 165: 195-205.

[69] Liu D, Yang P, Gao M, Yu T, Shi Y, Zhang M, et al. NLRP3 activation induced by neutrophil extracellular traps sustains inflammatory response in the diabetic wound. Clinical science (London, England: 1979). 2019; 133: 565-82.

[70] Xiao M, Li L, Li C, Liu L, Yu Y, Ma L. 3,4-Methylenedioxy-β-Nitrostyrene ameliorates experimental burn wound progression by inhibiting the NLRP3 Inflammasome activation. Plast Reconstr Surg. 2016; 137: 566e-75.

[71] Osuka A, Hanschen M, Stoecklein V, Lederer JA. A protective role for inflammasome activation following injury. Shock (Augusta, Ga). 2012; 37: 47-55.

[72] Stanojcic M, Chen P, Harrison RA, Wang V, Antonyshyn J, Zúñiga-Pflücker JC, et al. Leukocyte infiltration and activation of the NLRP3 inflammasome in white adipose tissue following thermal injury. Crit Care Med. 2014; 42: 1357-64.

[73] Louiselle AE, Niemiec SM, Zgheib C, Liechty KW. Macrophage polarization and diabetic wound healing. Translational research: the journal of laboratory and clinical medicine. 2021; 236: 109.

[74] Diao L, Patsouris D, Sadri AR, Dai X, Amini-Nik S, Jeschke MG. Alternative mechanism for white adipose tissue lipolysis after thermal injury. Molecular medicine (Cambridge, Mass). 2016; 21: 959-68.

[75] Mirza RE, Fang MM, Weinheimer-Haus EM, Ennis WJ, Koh TJ. Sustained inflammasome activity in macrophages impairs wound healing in type 2 diabetic humans and mice. Diabetes. 2014; 63: 1103-14.

[76] Wan L, Bai X, Zhou Q, Chen C, Wang H, Liu T, et al. The advanced glycation end-products (AGEs)/ROS/NLRP3 inflammasome axis contributes to delayed diabetic corneal wound healing and nerve regeneration. Int J Biol Sci. 2022; 18: 809-25.

[77] Gauglitz GG, Herndon DN, Kulp GA, Meyer WJ, 3rd, Jeschke MG. Abnormal insulin sensitivity persists up to three years in pediatric patients post-burn. J Clin Endocrinol Metab. 2009; 94: 1656-64.

[78] Gomez R, Murray CK, Hospenthal DR, Cancio LC, Renz EM, Holcomb JB, et al. Causes of mortality by autopsy findings of combat casualties and civilian patients admitted to a burn unit. J Am Coll Surg. 2009; 208: 348-54.

[79] Silva L, Garcia L, Oliveira B, Tanita M, Festti J, Cardoso L, et al. Acute respiratory distress syndrome in burn patients: incidence and risk factor analysis. Annals of burns and fire disasters. 2016; 29: 178-82.

[80] Foncerrada G, Culnan DM, Capek KD, González-Trejo S, Cambiaso-Daniel J, Woodson LC, et al. Inhalation injury in the burned patient. Ann Plast Surg. 2018; 80: S98-s105.

[81] Bai C, Li T, Sun Q, Xin Q, Xu T, Yu J, et al. Protective effect of baicalin against severe burn-induced remote acute lung injury in rats. Mol Med Rep. 2018; 17: 2689-94.

[82] Han S, Cai W, Yang X, Jia Y, Zheng Z, Wang H, et al. ROS-mediated NLRP3 Inflammasome activity is essential for burn-induced acute lung injury. Mediat Inflamm. 2015; 2015: 1-16.

[83] Luo N, Lin H, Zhang L, Jiang Y, Zhao Y, Han Q, et al. Effect of hydrogen on AM Pyroptosis induced by severe burns in rats. Journal of personalized medicine. 2023; 13: 377. https://doi.org/10.3390/jpm13030377.

[84] Xiao MJ, Zou XF, Li B, Li BL, Wu SJ, Zhang B. Simulated aeromedical evacuation exacerbates burn induced lung injury: targeting mitochondrial DNA for reversal. Military Medical Research. 2021; 8: 30.

[85] Vinaik R, Barayan D, Auger C, Abdullahi A, Jeschke MG. Regulation of glycolysis and the Warburg effect in wound healing. JCI Insight. 2020; 5:e138949. https://doi.org/10.1172/jci.insight.138949.

[86] Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Molecular medicine (Cambridge, Mass). 2011; 17: 113-25.

[87] Russo S, Kwiatkowski M, Govorukhina N, Bischoff R, Melgert BN. Meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: the importance of metabolites. Front Immunol. 2021; 12: 746151.

[88] Cavalcante-Silva J, Koh TJ. Targeting the NOD-like receptor pyrin domain containing 3 Inflammasome to improve healing of diabetic wounds. Adv Wound Care (New Rochelle). 2022; 12: 644-56.

[89] Chi Y, Chai J, Xu C, Luo H, Zhang Q. Apelin inhibits the activation of the nucleotide-binding domain and the leucine-rich, repeat-containing family, pyrin-containing 3 (NLRP3) inflammasome and ameliorates insulin resistance in severely burned rats. Surgery. 2015; 157: 1142-52.

[90] Deuis JR, Yin K, Cooper MA, Schroder K, Vetter I. Role of the NLRP3 inflammasome in a model of acute burn-induced pain. Burns: journal of the International Society for Burn Injuries. 2017; 43: 304-9.

[91] Lee JS, Robertson AAB, Cooper MA, Khosrotehrani K. The small molecule NLRP3 Inflammasome inhibitor MCC950 does not Alter wound healing in obese mice. Int J Mol Sci. 2018; 19: 3289. https://doi.org/10.3390/ijms19113289.

[92] Bian F, Xiao Y, Zaheer M, Volpe EA, Pflugfelder SC, Li DQ, et al. Inhibition of NLRP3 Inflammasome pathway by butyrate improves corneal wound healing in corneal alkali burn. Int J Mol Sci. 2017; 18: 562. https://doi.org/10.3390/ijms18030562.

[93] Vande Walle L, Stowe IB, Šácha P, Lee BL, Demon D, Fossoul A, et al. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. PLoS Biol. 2019; 17: e3000354. https://doi.org/10.1371/journal.pbio.3000354.

[94] Zeng W, Wu D, Sun Y, Suo Y, Yu Q, Zeng M, et al. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages. Sci Rep. 2021; 11: 19305.

[95] Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015; 21: 248-55.

[96] Wang Y, Wan L, Zhang Z, Li J, Qu M, Zhou Q. Topical calcitriol application promotes diabetic corneal wound healing and reinnervation through inhibiting NLRP3 inflammasome activation. Exp Eye Res. 2021; 209: 108668.

[97] Guo L, Wang Z, Zhu C, Li J, Cui L, Dong J, et al. MCC950 inhibits the inflammatory response and excessive proliferation of canine corneal stromal cells induced by staphylococcus pseudintermedius. Mol Immunol. 2022; 152: 162.

[98] Kolterman OG. Glyburide in non-insulin-dependent diabetes: an update. Clin Ther. 1992; 14: 196-213.

[99] Shao H, Huang L, Duan S, Gao M, Zhu J, Chen X, et al. Glyburide attenuates ozone-induced pulmonary inflammation and injury by blocking the NLRP3 inflammasome. Environ Toxicol. 2020; 35: 831-9.

[100] Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009; 187: 61-70.

[101] Wang Y, Zhang XL, Sun CM. BAY-11-7082 induces apoptosis of multiple myeloma U266 cells through inhibiting NF-κB pathway. Eur Rev Med Pharmacol Sci. 2018; 22: 2564-71.

[102] Strickson S, Campbell DG, Emmerich CH, Knebel A, Plater L, Ritorto MS, et al. The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. The Biochemical journal. 2013; 451: 427-37.

[103] Irrera N, Vaccaro M, Bitto A, Pallio G, Pizzino G, Lentini M, et al. BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis. Clinical science. London, England: 1979. 2017; 131: 487-98.

[104] Jiang W, Li M, He F, Zhou S, Zhu L. Targeting the NLRP3 inflammasome to attenuate spinal cord injury in mice. J Neuroinflammation. 2017; 14: 207.

[105] Bitto A, Altavilla D, Pizzino G, Irrera N, Pallio G, Colonna MR, et al. Inhibition of inflammasome activation improves the impaired pattern of healing in genetically diabetic mice. Br J Pharmacol. 2014; 171: 2300-7.

[106] Messerschmitt PJ, Rettew AN, Schroeder NO, Brookover RE, Jakatdar AP, Getty PJ, et al. Osteosarcoma phenotype is inhibited by 3,4-Methylenedioxy-β-nitrostyrene. Sarcoma. 2012; 2012: 1-11.

[107] Wang WY, Hsieh PW, Wu YC, Wu CC. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007; 74: 601-11.

[108] He Y, Varadarajan S, Muñoz-Planillo R, Burberry A, Nakamura Y, Núñez G. 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014; 289: 1142-50.

[109] Long H, Xu B, Luo Y, Luo K. Artemisinin protects mice against burn sepsis through inhibiting NLRP3 inflammasome activation. Am J Emerg Med. 2016; 34: 772-7.